Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
After finishing at $7.83 in the prior trading day, Atara Biotherapeutics Inc (NASDAQ: ATRA) closed at $6.57, down -16.09%. In other words, the price has decreased by -$16.09 from its previous closing price. On the day, 0.93 million shares were traded. ATRA stock price reached its highest trading level at $7.9642 during the session, while it also had its lowest trading level at $6.5605.
Ratios:
Our goal is to gain a better understanding of ATRA by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.50 and its Current Ratio is at 0.59.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Mizuho on November 09, 2023, Downgraded its rating to Neutral and sets its target price to $1 from $31 previously.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 18 ’24 when Henrich Jill sold 1,000 shares for $11.20 per share. The transaction valued at 11,198 led to the insider holds 19,378 shares of the business.
Hyllengren Eric J sold 1,364 shares of ATRA for $15,274 on Nov 18 ’24. The EVP, CFO and COO now owns 23,392 shares after completing the transaction at $11.20 per share. On Nov 18 ’24, another insider, Nguyen AnhCo, who serves as the President and CEO of the company, sold 1,664 shares for $11.20 each. As a result, the insider received 18,633 and left with 77,454 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ATRA now has a Market Capitalization of 37841560 and an Enterprise Value of 87498600. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.38. Its current Enterprise Value per Revenue stands at 1.403 whereas that against EBITDA is -0.54.
Stock Price History:
The Beta on a monthly basis for ATRA is 0.50, which has changed by -0.56272876 over the last 52 weeks, in comparison to a change of 0.23631513 over the same period for the S&P500. Over the past 52 weeks, ATRA has reached a high of $39.50, while it has fallen to a 52-week low of $6.50. The 50-Day Moving Average of the stock is -46.37%, while the 200-Day Moving Average is calculated to be -42.54%.
Shares Statistics:
The stock has traded on average 159.24K shares per day over the past 3-months and 506660 shares per day over the last 10 days, according to various share statistics. A total of 5.74M shares are outstanding, with a floating share count of 4.31M. Insiders hold about 25.12% of the company’s shares, while institutions hold 42.26% stake in the company. Shares short for ATRA as of 1730332800 were 636280 with a Short Ratio of 3.35, compared to 1727654400 on 526379. Therefore, it implies a Short% of Shares Outstanding of 636280 and a Short% of Float of 11.359999.
Earnings Estimates
Atara Biotherapeutics Inc (ATRA) is presently subject to a detailed evaluation by 2.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.16, with high estimates of $3.05 and low estimates of -$3.37.
Analysts are recommending an EPS of between -$0.8 and -$2.23 for the fiscal current year, implying an average EPS of -$1.51. EPS for the following year is -$12.02, with 4.0 analysts recommending between -$1.19 and -$20.49.
Revenue Estimates
4 analysts predict $24.3M in revenue for the current quarter. It ranges from a high estimate of $40.19M to a low estimate of $14M. As of the current estimate, Atara Biotherapeutics Inc’s year-ago sales were $4.25MFor the next quarter, 4 analysts are estimating revenue of $29.9M. There is a high estimate of $60.7M for the next quarter, whereas the lowest estimate is $14M.
A total of 3 analysts have provided revenue estimates for ATRA’s current fiscal year. The highest revenue estimate was $136.38M, while the lowest revenue estimate was $110M, resulting in an average revenue estimate of $122.79M. In the same quarter a year ago, actual revenue was $8.57MBased on 6 analysts’ estimates, the company’s revenue will be $82.39M in the next fiscal year. The high estimate is $155M and the low estimate is $38M.
